com)-- Roots Analysis has announced the addition of "Non-Tyrosine Kinase
Inhibitors in Oncology, 2015-2025" report to their offering.
com/research/42hpkb/nontyrosine) has announced the addition of the "Non-Tyrosine Kinase
Inhibitors in Oncology, 2015 - 2025" report to their offering.
Molecular biologists, biochemists, pharmaceutical chemists, and other researchers highlight the therapeutic potential of kinase
inhibitors to disrupt the role they play in tumor progression and several other diseases.
In this work, Matthews (executive director of oncology discovery at Exelixis, "an integrated drug discovery and development company") and Gerritsen (vice president of molecular and cellular pharmacology also at Exelixis) provide a broad, if necessarily selective, treatment of kinase
cancer targets and the drugs that inhibit them, with a focus on small molecule inhibitors.
The study, led by University of Iowa scientists, demonstrated in theory, that it might be possible to use drugs that maintain the positive effects on heart function of a known enzyme called calmodulin kinase
II (CaM kinase
) while reducing its negative effects.
These effects are regulated by complex intracellular signaling pathways including MAPKs, phospholipase C, protein kinase
C, and phospholipase A2.
Kinexus Bioinformatics Corporation, Vancouver, a Canadian proteomics company, has announced the validation of its unique approach for protein kinase
drug target discovery with the publication of its latest research findings in the September printed issue of the Journal of Biological Chemistry.
This invention provides a fusion protein comprising a PAK4 serine/threonine kinase
or a fragment thereof and a second peptide.
EphB4 is a receptor tyrosine kinase
that is expressed on epithelial cells during fetal life.
Our studies demonstrate HIV-1 gp120 elicits several different types of signals in macrophages through CXCR4 and CCR5, including calcium elevations, ionic channel activation, non-receptor protein tyrosine kinase
activation, and activation of MAP kinases
This mutation encodes an enzyme, Bcr-Abl tyrosine kinase
, that causes white blood cells to proliferate.
DiscoveRx announced today the release of the most detailed comprehensive assessment of interaction profiles of known kinase
inhibitors across the kinome published to date in the November 2011 issue of Nature Biotechnology, titled"Comprehensive analysis of kinase